Valuation: Orion Oyj

Capitalization 9.48B 11.11B 8.69B 8.23B 15.25B 1,064B 15.4B 104B 40.32B 505B 41.71B 40.83B 1,753B P/E ratio 2026 *
17.4x
P/E ratio 2027 * 15.1x
Enterprise value 9.4B 11.02B 8.62B 8.16B 15.12B 1,055B 15.26B 103B 39.97B 500B 41.34B 40.47B 1,738B EV / Sales 2026 *
4.55x
EV / Sales 2027 * 3.97x
Free-Float
90.38%
Yield 2026 *
2.81%
Yield 2027 * 3.05%
1 day-0.07%
1 week-5.07%
Current month-1.89%
1 month-7.10%
3 months-0.66%
6 months+12.61%
Current year+5.89%
1 week 65.1
Extreme 65.1
71
1 month 65.1
Extreme 65.1
75.3
Current year 62.7
Extreme 62.7
75.3
1 year 54.15
Extreme 54.15
75.3
3 years 31.86
Extreme 31.86
75.3
5 years 31.86
Extreme 31.86
75.3
10 years 22.57
Extreme 22.57
75.3
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5d. change 1-year change 3-years change Capi.($)
-0.07%-5.07%+21.66%+59.72% 11.11B
+2.37%+0.10%+31.01%+127.85% 883B
+1.28%-0.57%+45.49%+39.48% 540B
+2.51%+0.85%+9.36%+41.26% 367B
+1.08%-1.00%+20.39%+10.73% 328B
-0.95%+0.50%+33.93%+13.62% 288B
+0.13%+0.43%+28.90%+25.57% 283B
+0.98%-0.69%+39.71%-4.07% 278B
+1.49%+2.59%-31.46%-48.26% 206B
+2.03%+2.03%+22.39%+44.36% 181B
Average +0.31%+0.59%+22.14%+31.03% 336.48B
Weighted average by Cap. +0.24%+0.59%+26.40%+48.03%

Financials

2026 *2027 *
Net sales 2.07B 2.42B 1.9B 1.79B 3.32B 232B 3.36B 22.57B 8.79B 110B 9.09B 8.9B 382B 2.31B 2.71B 2.12B 2B 3.71B 259B 3.75B 25.21B 9.82B 123B 10.15B 9.94B 427B
Net income 543M 637M 498M 472M 874M 60.96B 882M 5.93B 2.31B 28.91B 2.39B 2.34B 100B 628M 736M 576M 545M 1.01B 70.46B 1.02B 6.86B 2.67B 33.42B 2.76B 2.7B 116B
Net Debt -82.12M -96.28M -75.31M -71.29M -132M -9.22B -133M -897M -349M -4.37B -361M -354M -15.19B -308M -361M -282M -267M -495M -34.54B -500M -3.36B -1.31B -16.38B -1.35B -1.33B -56.92B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,132
Date Price Change Volume
26-05-13 67.35 0.00% 23,316
26-05-12 67.35 +0.22% 115,401
26-05-11 67.20 -1.97% 178,310
26-05-08 68.55 -1.44% 97,067
26-05-07 69.55 -2.04% 169,890
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
67.35EUR
Average target price
74.17EUR
Spread / Average Target
+10.12%

Quarterly revenue - Rate of surprise